|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-5-15
|
|
pubmed:abstractText |
Despite chemotherapy and radiotherapy for small cell lung cancer (SCLC), most patients die within 2 years. Response rates for second-line chemotherapy are 15-25%, with a median survival of 5 months. Caelyx, a pegylated liposomal formulation of doxorubicin, may be better tolerated and has activity in SCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
pubmed-author:BurkesR LRL,
pubmed-author:DanceyJ EJE,
pubmed-author:GossG DGD,
pubmed-author:LeighlNatasha BNB,
pubmed-author:LopezP GPG,
pubmed-author:PondG RGR,
pubmed-author:PouliotJ FJF,
pubmed-author:RahimY HYH,
pubmed-author:RodgersAA,
pubmed-author:RudinskasL CLC,
pubmed-author:ShepherdF AFA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
327-32
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16597474-Adult,
pubmed-meshheading:16597474-Aged,
pubmed-meshheading:16597474-Aged, 80 and over,
pubmed-meshheading:16597474-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16597474-Carcinoma, Small Cell,
pubmed-meshheading:16597474-Cyclophosphamide,
pubmed-meshheading:16597474-Disease-Free Survival,
pubmed-meshheading:16597474-Doxorubicin,
pubmed-meshheading:16597474-Female,
pubmed-meshheading:16597474-Humans,
pubmed-meshheading:16597474-Lung Neoplasms,
pubmed-meshheading:16597474-Male,
pubmed-meshheading:16597474-Middle Aged,
pubmed-meshheading:16597474-Neoplasm Recurrence, Local,
pubmed-meshheading:16597474-Salvage Therapy,
pubmed-meshheading:16597474-Survival Rate,
pubmed-meshheading:16597474-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
|
|
pubmed:affiliation |
Princess Margaret Hospital/University of Toronto, Department of Medicine, 5-222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9. Natasha.Leighl@uhn.on.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
